BRISBANE, Calif. / Jun 01, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.
CareDx’s management is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023, at 8:00 AM PT / 11:00 AM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com.
CareDx’s management will also be presenting at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th, 2023, at 4:40 PM PT / 7:40 PM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
| Last Trade: | US$17.72 |
| Daily Change: | 0.44 2.55 |
| Daily Volume: | 1,024,580 |
| Market Cap: | US$950.320M |
February 26, 2025 February 20, 2025 February 13, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
